Novo Nordisk reported on July 31 that its experimental heart drug ziltivekimab did what it was designed to do biologically and produced no measurable clinical benefit. In a trial of more than 6,300 patients, the drug lowered inflammatory markers as expected but did not reduce cardiovascular death, non-fatal heart attack, or non-fatal stroke compared with placebo.
The hazard ratio was 0.99, with a 95 percent confidence interval of 0.88 to 1.11. In plain terms, the treated group and the placebo group had essentially identical outcomes.
Nothing about this changes what any patient should do today. No approved therapy was withdrawn, no guideline was revised, and ziltivekimab was never available outside a trial. What the result does is unsettle a scientific idea that has shaped a decade of cardiovascular drug development and that patients have increasingly encountered through inflammation blood tests ordered at checkups.
The Result Novo Nordisk Reported
ZEUS was a double-blind, placebo-controlled Phase 3 cardiovascular outcomes trial. It enrolled more than 6,300 people who had atherosclerotic cardiovascular disease, chronic kidney disease, and inflammation defined as a high-sensitivity C-reactive protein level of at least 2 milligrams per liter.
Participants received either a once-monthly 15-milligram dose of ziltivekimab or placebo. The primary endpoint was the composite of cardiovascular death, non-fatal heart attack, and non-fatal stroke.
According to Novo Nordisk's announcement, the drug engaged its target and produced the expected reductions in free interleukin-6 and hsCRP. Martin Holst Lange, the company's executive vice president, chief scientific officer, and head of research and development, said that "although ziltivekimab produced the expected biological effect, this did not result in MACE benefits in this population."
Overall adverse event and serious adverse event rates were similar between groups, though serious infections were more frequent among those receiving the drug, which the company described as consistent with blocking the IL-6 pathway. No difference in all-cause mortality was observed. As TCTMD noted in its summary, these are topline figures released by the sponsor. Novo Nordisk manufactures ziltivekimab and funded the trial, and clinical coverage of the readout noted the company's statement that more detail on adverse event rates and discontinuations will come with full results.
The Theory the Trial Was Built to Test
The inflammatory hypothesis holds that atherosclerosis is not simply cholesterol accumulating in artery walls but an active inflammatory process, and that damping that inflammation should reduce events independently of lowering cholesterol.
The idea had strong support. Laboratory and animal work established inflammation's role at every stage of plaque development. A 2017 trial of canakinumab, published in the New England Journal of Medicine, showed that targeting interleukin-1 beta reduced cardiovascular events without changing lipid levels, which was widely treated as proof of principle. Colchicine trials produced a more mixed record, with some studies in chronic and acute coronary syndromes showing event reductions and a large trial in patients after heart attack showing no benefit.
ZEUS was the most direct test yet of the next step in that chain. Interleukin-6 sits downstream of interleukin-1 in the pathway and upstream of C-reactive protein, and blocking it was expected to be a cleaner intervention than earlier attempts.
The gap between mechanism and outcome is what makes the result instructive. The drug moved the biomarkers. The biomarkers did not carry the clinical benefit with them. That dissociation is a caution about treating hsCRP reduction as a proxy for patient benefit, and it lands in a field where inflammatory markers have been used as risk-enhancing factors in prevention guidelines.
Patients Currently Taking Anti-Inflammatory Heart Therapy
Some patients are prescribed low-dose colchicine for cardiovascular risk reduction, and this result does not apply to them directly. Colchicine works through a different mechanism and was tested in different populations.
Nobody should stop a prescribed medication based on a trial of a different drug in a different population. That decision belongs with a cardiologist who knows the patient's history.
For patients who have had an hsCRP test, the practical takeaway is narrower than it may appear. An elevated inflammatory marker still identifies higher cardiovascular risk. What ZEUS undercuts is the assumption that lowering that specific marker with this specific mechanism reduces the risk it identifies. Risk marker and treatment target are not the same thing.
The proven levers remain the proven levers. Lipid lowering, blood pressure control, smoking cessation, diabetes management, and physical activity all have outcome trial evidence behind them. A negative result in an experimental pathway does not weaken any of them.
Remaining Trials and Unanswered Questions
ZEUS enrolled a specific population, people with established cardiovascular disease plus chronic kidney disease plus elevated inflammation, and that specificity limits how far the result generalizes. Whether IL-6 inhibition might help a different population, or work if started earlier in the disease process, remains untested.
Two other ziltivekimab outcomes trials are continuing. As reported in trial coverage of the readout, HERMES is studying the drug in people with heart failure and ARTEMIS is testing it in patients following an acute heart attack, with both anticipated to read out in the first half of 2027. Those readouts will do more to define the boundaries of this result than commentary can.
Full ZEUS results are scheduled for presentation at a scientific meeting later this year, which will provide the detail on adverse events, discontinuations, and subgroups that topline figures cannot. Industry coverage of the announcement also noted the company's statement that the outcome will not affect its 2026 adjusted operating profit outlook but will produce a non-cash impairment charge in the third quarter.
Patients with questions about their own inflammatory markers or cardiovascular risk should raise them at their next appointment rather than acting on a trial announcement. The most reasonable reading is that a promising pathway did not deliver in one carefully defined group, and that the established prevention tools are unchanged.
Key Questions Answered
What happened? Novo Nordisk reported that ziltivekimab, an IL-6 inhibitor, reduced inflammatory markers as expected but did not reduce cardiovascular death, heart attack, or stroke in a trial of more than 6,300 patients.
Who was in the trial? People with atherosclerotic cardiovascular disease, chronic kidney disease, and inflammation measured by hsCRP of at least 2 milligrams per liter.
Does this mean inflammation does not matter in heart disease? No. Inflammation remains a marker of higher risk, and an earlier trial of a different anti-inflammatory drug showed benefit. What this trial did not show is that blocking IL-6 in this population translates biomarker changes into fewer events.
Should anyone stop taking a heart medication? No. Ziltivekimab was never approved or available outside trials, and no approved therapy changed. Do not stop a prescribed medication without speaking with your clinician.
What about colchicine? Colchicine works through a different mechanism and was tested in different populations, so this trial does not apply to it directly.
Was there a safety problem? Overall adverse event rates were similar between groups, but serious infections were more frequent with the drug, which the company said is consistent with IL-6 pathway inhibition.
What comes next? Full results are due at a scientific meeting later this year. Two other trials, HERMES in heart failure and ARTEMIS after heart attack, are anticipated to read out in the first half of 2027.
